Yuhan Corp’s EGFR-targeting anticancer drug ‘Leclaza’ has started to accumulate data for the international stage.

At the ‘2023 ASCO Annual Meeting (ASCO 2023)’ that was held on the 2nd (local time), Yuhan Corp made 4 poster presentations on studies related to its Leclaza, including one long-term follow-up study. With the results of Janssen’s main MARIPOSA study expected to be released in the second half of this year, initial research results that give a glimpse of the MARIPOSA study have also been updated.

Leclaza is a treatment for non-small-cell lung cancer that was approved as the 31st homegrown novel drug in January 2021. It is a 3rd generation EGFR TKI that inhibits th